Reuters
Published Oct 03, 2023 12:20PM ET
(Reuters) - Manufacturers of the 10 prescription drugs subject to price negotiations for the U.S. Medicare program have signed on to participate in the talks by the Oct. 1 deadline even as Novo Nordisk (NYSE:NVO) filed a lawsuit to halt the process.At least nine lawsuits were filed between June and late September seeking to block the price negotiation, arguing that the law and forced price cuts would violate various amendments to the U.S. constitution.
The following are key details of the lawsuits:
Company Date Location Drugs named in
filed lawsuit as
likely to be
affected by IRA
Merck & Co June 6 U.S. District Court Diabetes drugs
for the District of Januvia and
Columbia Janumet, cancer
treatment
Keytruda
The U.S. June 9 U.S. District Court NA
Chamber of for the Southern
Commerce District Of Ohio
Western Division
Bristol Myers (NYSE:BMY) June 16 U.S. District Court Blood thinner
Squibb for the District of Eliquis, cancer
New Jersey therapy Opdivo
Johnson & July 18 U.S. District Court Blood thinner
Johnson for the District of Xarelto
New Jersey
Pharmaceutica June 21 U.S. District Court NA
l Research For the Western
and District Of Texas
Manufacturers Austin Division
of America
Boehringer Aug 18 U.S. District Court Diabetes drug
Ingelheim for the District Of Jardiance
Connecticut
AstraZeneca (NASDAQ:AZN) Aug 25 U.S. District Court Cancer drug
For the District Of Lynparza, blood
Delaware disorder
treatment
Soliris
Novartis (SIX:NOVN) Sept 1 U.S. District Court Heart-failure
for the District of drug Entresto
New Jersey
Novo Nordisk Sept 29 U.S. District Court Insulin Aspart
for the District of for Diabetes
New Jersey
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.